Intravitreal Ziv-Aflibercept: safety analysis
7 December 2020
| Su Young
|
Retina / Uvea / Vitreous
|
Diabetic macular edema (DME), Intravitreal ziv, aflibercept (IVZ), Neovascular age related macular degeneration (n, AMD), Ziv, aflibercept, retinal venous occlusion (RVO)
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
